Modality
Multispecific
MOA
HPK1i
Target
APOC3
Pathway
Proteasome
PBC
Development Pipeline
Preclinical
~Sep 2015
→ ~Dec 2016
Phase 1
~Mar 2017
→ ~Jun 2018
Phase 2
~Sep 2018
→ ~Dec 2019
Phase 3
~Mar 2020
→ ~Jun 2021
NDA/BLA
Sep 2021
NDA/BLACurrent
NCT07434317
535 pts·PBC
2021-09→TBD·Completed
535 total pts1 indication
Approved
CompletedCurrentUpcoming
Trial Timeline
NDA/BLA
Complet…
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07434317 | NDA/BLA | PBC | Completed | 535 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Talasotorasib | Exelixis | Preclinical | APOC3 |